Editorial Policy

Sourcing standards

• Peer-reviewed research comes first. Where a claim rests on a published study, we cite it and link to PubMed or the journal so you can read the original.
• Primary trials outrank secondary summaries. If a review article makes a claim, we go to the trial it cites rather than repeating the summary.
• Regulatory sources (FDA, EMA) are used for approval status, warning letters, and safety communications. Approval status is stated as of a specific date, because it changes.
• Anecdotal and community-reported practice is labeled as such, never presented as evidence. When practitioners commonly do something the literature has not studied, we say both halves of that sentence.
• Vendor marketing material is not a source for any efficacy or safety claim.

Dosage claims

Dosing is the highest-risk content we publish, so it carries the strictest rule: every dose figure has to be traceable to the study, trial protocol, or clinical source it came from. Where a dose is extrapolated from animal data, we say it is extrapolated from animal data. Where human data does not exist, we say that rather than filling the gap with a plausible-sounding number.

Our calculators apply arithmetic to inputs you provide. They do not decide whether a compound is appropriate for you, and they are not a substitute for clinical supervision.

Review before publishing

Nothing publishes on the strength of one person's reading. Before an article goes live, its factual claims are checked back against the sources cited, dosage figures are verified against the study or protocol they came from, and safety and interaction warnings are confirmed against current literature and regulatory communications. Claims that cannot be traced to a source are cut rather than softened.

Where an article names a reviewer, that person has read it and signed off on its clinical claims. We do not attach a name or a credential to work it did not review.

Independence and conflicts of interest

PeptidesExplorer is funded by sales of our personalized protocol product. We do not accept payment from peptide suppliers, compounding pharmacies, or telehealth providers in exchange for coverage, placement, or a favorable review. No vendor sees an article before it publishes. Where any commercial relationship exists, it is disclosed on the page it affects.

Updates and corrections

Peptide research moves, and regulatory status moves faster. We revisit articles when new trial data publishes, when approval status changes, or when a reader flags an error. Substantive updates change the article's modified date; fixing a typo does not.

If you find a factual error, email support@peptidesexplorer.com with the article and the source that contradicts it. We verify against the primary literature and correct what is wrong. Corrections that change a dosage, a safety warning, or a factual conclusion are noted on the article itself rather than quietly edited.

Scope and limits

This site is educational. It does not diagnose, treat, or prescribe, and it cannot account for your medical history, medications, or lab work. Most compounds covered here are not approved for human use. Talk to a qualified healthcare provider before acting on anything you read on this site.